These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9609063)

  • 1. [Medical treatment of prolactin and growth hormone-secreting pituitary tumors].
    Jadresic A
    Rev Med Chil; 1997 Nov; 125(11):1383-8. PubMed ID: 9609063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Results of treatment for male prolactinomas].
    Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
    No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Possibilities of medical treatment in acromegaly].
    Cáp J; Nemecek S; Rezácová M; Cerman J
    Cas Lek Cesk; 2005; 144 Suppl 3():33-4, 36-7. PubMed ID: 16335261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin excess: treatment and toxicity.
    Gillam MP; Fideleff H; Boquete HR; Molitch ME
    Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():108-14. PubMed ID: 16456489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of resistant prolactinomas.
    Olafsdottir A; Schlechte J
    Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine Agonists: From the 1970s to Today.
    Auriemma RS; Pirchio R; De Alcubierre D; Pivonello R; Colao A
    Neuroendocrinology; 2019; 109(1):34-41. PubMed ID: 30852578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of prolactinomas and growth hormone-producing adenomas with an injectable bromocriptine retard preparation and a somatostatin analogue delivered by an implantable pump.
    Schatz H; Stracke H; Hildebrandt G
    Pathol Res Pract; 1988 Sep; 183(5):546-51. PubMed ID: 3237541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin-secreting tumors: what's new?
    Molitch ME
    Expert Rev Anticancer Ther; 2006 Sep; 6 Suppl 9():S29-35. PubMed ID: 17004854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Criteria for medical as opposed to surgical treatment of prolactinomas.
    Besser M
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():27-30. PubMed ID: 8103956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Dopamine Agonists in Pituitary Adenomas.
    Giraldi EA; Ioachimescu AG
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
    Miki N
    Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine receptor agonists for treating prolactinomas.
    Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
    Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical therapy of prolactinomas.
    Jaquet P
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():31-3. PubMed ID: 8103957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
    Merola B; Colao A; Caruso E; Sarnacchiaro F; Briganti F; Lancranjan I; Lombardi G; Schettini G
    Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future treatment strategies of aggressive pituitary tumors.
    Lamberts SW; Hofland LJ
    Pituitary; 2009; 12(3):261-4. PubMed ID: 19003539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.